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Prescribed since the 1950’s for 
patients with atrial fibrillation, 
deep vein thrombosis, 
pulmonary emboli and 
prosthetic heart valves. 
Adverse effects can be life 
threatening and costly.
Many emergency department 
hospitalizations are due to 
unintentional overdoses.
Literature review showed a 
nationwide problem in the 
management of patients on this 
therapy.
Due to its extensive drug 
interaction profile, it requires 
frequent monitoring and dose 
adjustments.
In order for the medication to 
work appropriately, patients 
must have INR testing to 
determine whether they are in 
therapeutic range.
Management is complex 
because of its intricate 
pharmacokinetic, 
pharmacodynamic properties, 




Leading cause of drug related adverse events at South 
Miami Hospital prior to the clinic opening.
Resulting in 27 hospital admissions a year. 
Patients had prolonged hospital stays due to sub 
therapeutic INRs and frequent ED visits due to warfarin 
toxicity.
A retrospective chart review revealed that patients were 
being discharged without a clear plan for follow up and 
management.
General lack of knowledge among patients taking Warfarin 
in regards to strength, use and effect.
Serious and sometimes fatal warfarin and heparin toxicity 
issues were being experienced throughout our own 
community as evidenced by our Emergency Department 
reports of frequent readmissions. 
BRANDS AND STRENGTHS
ENGAGING IN A QUALITY IMPROVEMENT PROJECT
• An interdisciplinary team was formed to 
address this problem.
• Nurses, doctors, and nurse practitioners.
• Decision was made to create an 
anticoagulation clinic to address the 
number of patients going to the 
emergency room due to warfarin toxicity.
• In 2007 South Miami Hospital 
Anticoagulation Clinic opened its door. 
PROJECT GOAL
• The foundation of our efforts in the development of an 
Anticoagulation Clinic was to:
• Improve the quality of life
• Educate the community
• Decrease time in the hospital
• Enhance the effectiveness and compliance of treatment 
plans
• Mitigate the risks associated with the use of 
anticoagulants
• The primary goal of service was to act as a bridge in the 






dependent on nurses’ 
care.  
OUTREACH PROGRAM
• Charity care program which provides 
office visits and point of care testing to 
those that meet the criteria. 
• This program has allowed us to care for 
the patients who would normally have 
limited resources, and in turn provide 
education and assist them in becoming 
proactive in their own health care. 
PATIENT SAFETY ACCOMPLISHMENTS
• Safely patient discharge with an immediate follow-up 
visit by the clinic staff for INR adjustments. 
• Patients are discharged earlier and monitored 
frequently which has reduced anticoagulation related 
readmissions.
• Reduction in hospital costs and improvement in 
patient outcomes. 
• Clinic has grown in volume and has been successful in 
monitoring outpatient anticoagulation therapy, 
providing patient continuity of care, increasing patient 
safety, decreasing patient complications, and number 
of adverse drug reactions. 
ANTICOAGULATION CLINIC
Nurses have a leading 
role in the clinic.
Convenient testing of 
patients’ INR using a 
finger stick. 
Within 15 seconds the 
result is available and the 
plan of care can be 
created.
Phlebotomy draw during 
patients’ visit.
RN or ARNP call patients 
to discuss the plan of 
care. 
Follow up appointments 
made by the clinical staff 
member during the visit.
SERVICES
• The clinic uses evidence-based guidelines to make 
dose adjustments and follow up intervals. 
• Any fluctuations in a patient’s INR levels are 
addressed. 
• Medications and changes in diet are monitored 
during each visit. 
• Patients are provided with continued support by 
the clinic’s staff. 
Order and Dosing Protocol
Warfarin Dose Adjustment (mg) – Use column that reflects Desired range 
All dosages are supervised and approved by ARNP or Medical Director 
INR 2.0 to 3.0 2.5 to 3.5
<1.5 ↑Weekly dose by 5% to 10% ↑Weekly dose by 15% to 20%
1.5 to 1.9 ↑Weekly dose by 5% to 10% ↑Weekly dose by 5% to 10%
2.0 to 2.4
Therapeutic;
no change in dose
↑Weekly dose by 5% to 10%
2.5 to 3.0
Therapeutic;
no change in dose
Therapeutic;
no change in dose
3.1 to 3.5 ↓Weekly dose by 5% to 10%
Therapeutic;
no change in dose
3.6 to 4.0
Hold 1 dose.
↓ Weekly dose by 5% to 10%
↓Weekly dose by 5% to 10%
4.1 to 6.0
Hold 1 to 2 doses.
↓Weekly dose by 15% to 20%
Hold 1 to 2 doses.
↓Weekly dose by 5% to 10%
>6 to <10
1. Assess for signs of bleeding, such as nosebleeds, bleeding from gums, unusual bleeding or 
bruising, red or dark brown urine, red or black stools.
2. If Vitamin K is ordered, the dose is:
a) 2.5 - 5 mg P.O. check INR in 24 -48h
b) If INR remains high, repeat vitamin K; repeat INR in 24 h and follow table above if INR is <6
c) If INR remains>6 after 2 doses of vitamin K, consult with physician
>10
1. Assess for signs of bleeding, such as nosebleeds, bleeding from gums, unusual bleeding or 
bruising, red or dark brown urine, red or black stools.
2. Consult with physician. Refer to ED if indicated. If vitamin K is ordered, the dose is: 5mg 
P.O.
a) Check INR in 24 h
b) If INR remains >10, give vitamin K 5 mg PO; repeat INR in 24 h and follow table above if INR 
is <10. Also, notify physician if INR remains >6











• Notice of non-compliance
• Yearly prescription renewal
• Consulting physician
• Bridging plan of care
• Anti-coagulant transition
ACHIEVING THE GOAL
• Since the clinic has opened, there has been a 
steady decrease in Coumadin related adverse 
events.  
• Prior to the anticoagulation clinic, there were 
between 22 – 27 hospital admissions related to 
Warfarin toxicity or complications.  
• Today the number has decreased significantly to 
less than 10 admissions per year and this 
number has been sustained.
MONITORING INRS & ADR
• Patients are carefully monitored and data 
regarding adverse drug related (ADR) 
admissions are analyzed and reported to the 
SMH Pharmacy and Therapeutics committee. 
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LESSONS LEARNED
It is evident that the anticoagulation clinic is a 
remarkable resource for education, monitoring, and 
Warfarin management.  
This model has been effective of reducing Warfarin 
toxicity admissions by 74% since its opening. 
Patients continue to appreciate the timeliness and 
convenience of their Warfarin management. 
PLAN
FUTURE GOALS 
•Development of a culturally sensitive 
teaching tool 
•Improvement of current educational 
materials
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